Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nexys Therapeutics Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action, which represents the entirety of the company's active prosecution in this field. This suggests a very focused intellectual property strategy for the organization.
The prosecution is concentrated under 1 distinct examiner within 1 distinct art unit. This lack of distribution means that the company's patent outcomes are not subject to the varied interpretations that come with multiple examiners or art units. The single art unit indicates that the technology being patented is classified within a specific, narrow segment of the Biotechnology & Pharmaceuticals sector.
NOTTINGHAM, KYLE GREGORY is the busiest examiner for this portfolio, currently responsible for 1 busiest examiner pending office action. Because this individual is handling the only active case, the company's immediate success in the patent office depends solely on this evaluation. Practitioners should analyze the specific patterns of NOTTINGHAM, KYLE GREGORY to effectively navigate the prosecution and secure the desired patent protection for this 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18795000 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NOTTINGHAM, KYLE GREGORY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18795000 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NOTTINGHAM, KYLE GREGORY | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18795000 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NOTTINGHAM, KYLE GREGORY | 1621 | §103§112 | Non-Final OA | — | Pending | Aug 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNexys Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kyle Gregory Nottingham has the most, with 1 of Nexys Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
